Since its June IPO debut, Electrocore Inc. has seen its valuation cut by more than half. Like many newly public med-tech companies, it's not profitable yet and relying solely on investor assessments of the eventual market for its technology. The Basking Ridge, N.J.-based company now has a new way to expand its revenue – an FDA clearance for its Gammacore handheld vagus nerve stimulator as an adjunct to standard of care to prevent cluster headaches. Read More
